BullFrog AI Q3 10-Q: Going Concern Persists Despite $5.0M Cash and $7.9M Raised
BFRG sits 27% above its 52-week low of $0.425.
Summary
BullFrog AI's Q3 2026 10-Q keeps the going-concern warning in place even after raising $7.9 million of net stock proceeds, leaving the company dependent on further equity sales and a possible reverse split to hold its Nasdaq listing.
Key Events · Earnings and Guidance · BFRG
-
Going Concern Warning Repeats
Management states cash and equivalents are not sufficient to fund planned operations for at least a year beyond the filing date, raising substantial doubt about the ability to continue as a going concern.
-
Cash Rises on $7.9M Stock Sales
Cash and cash equivalents reached $4,989,914 at September 30, 2026 versus $2,183,705 at December 31, 2025, after $7,851,626 of net proceeds from common stock sales, split roughly $5.8 million under the Lincoln Park ELOC and $2.0 million under the BTIG ATM.
-
Q3 Loss Widens as Costs Climb
Third-quarter net loss was $2,011,881 versus $1,551,612 a year earlier, with G&A up 31% to $1,622,565 and R&D up 27% to $439,240; the nine-month net loss was $4,976,572.
-
Nasdaq Bid-Price Deadline Looms
The second 180-day compliance period runs to February 8, 2027, and the company has told Nasdaq it intends to cure the sub-$1.00 bid by effecting a reverse split at a ratio between 1-to-2 and 1-to-15 if needed.
Analysis · BFRG · Life Sciences
BullFrog still cannot fund a year of operations from its own cash, so it remains dependent on selling stock through its ATM and Lincoln Park equity line. The quarter bought time, not a cure: cash rose to $4,989,914 from $2,183,705 at year-end on $7,851,626 of net stock sale proceeds, while the nine-month net loss was $4,976,572. Costs are climbing again, with Q3 G&A up 31% and R&D up 27% year over year, which shortens the runway the raise just extended. The Nasdaq bid-price clock runs to February 8, 2027, and management has said it will use a reverse split if the price does not recover on its own.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BFRG was trading at $0.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10M. The 52-week trading range was $0.43 to $1.96. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.